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Immunogenicity and Immune-Modulating 
Properties of Human Stem Cells 
Jan Nehlin, Adiba Isa and Torben Barington 
Odense University Hospital & University of Southern Denmark 
Denmark 
1. Introduction 
The future use of stem cell-based therapeutic applications in regenerative medicine is 
regarded as promising. In addition to autologous and allogeneic transplantation procedures, 
various innovative methods have been designed to generate patient-histocompatible stem 
cells from which lineage-specific cell progenies could be obtained (reviewed in Nehlin & 
Barington, 2009). Immunological aspects of the transplanted cells as well as the recipient 
need to be considered in order to predict the outcome of clinical cell therapies. 
Undifferentiated stem cells show initially a low degree of immunogenicity leading to weak 
immune responses when introduced into non-histocompatible hosts. In addition, stem cells 
possess immune-modulating properties that confer the capacity to withstand a cytotoxic 
response in a foreign host. The nature and significance of these strategies will be described 
in detail along this chapter. 
Many valuable contributions dealing with immunogenicity and immunological tolerance 
have been possible by means of mouse embryonic and multipotent stem cells. However, this 
overview will explore in-depth the immunological features and clinical uses of two types of 
human stem cells, embryonic stem cells (Figure 1) and multipotent mesenchymal stem cells 
(Figure 2 & 3) that allow them to be considered in transplantation procedures. 
2. Basic principles of antigen presentation, the adaptive immune response 
and immune histocompatibility 
The highly polymorphic classical “Major Histocompatibility Complex” (MHC) class I 
protein family consists of extracellular, membrane spanning, alpha chains HLA-A, -B, and -
C (Human leukocyte antigens) acting as ligands for T-lymphocyte receptors (TcR) expressed 
on T lymphocytes, the killer-immunoglobulin-like receptors (KIR) on Natural Killer (NK) 
cells and for certain members of the leukocyte immunoglobulin-like receptor (LILR / ILT / 
LIR) family. The non-classical MHC class I protein family include less polymorphic HLA 
members such as HLA-E, HLA-F, HLA-G, HLA-K and HLA-L (Li & Raghavan, 2010). 
A major function of HLA molecules is presentation of intracellularly produced self and non-
self peptides. During intracellular infection, pathogen-derived (non-self) peptides are 
presented by virtually all nucleated cells in the body to TcR of cytotoxic CD8+ T 
lymphocytes leading to killing of infected cells. Endogenous (self) peptides are also 
presented, but usually T cells with specificities to self-peptides are eliminated in the thymus. 
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The introduction of allogeneic stem cell-derived tissues into an immunocompetent recipient 
is likely to result in T-cell-mediated rejection by either of two mechanisms. One is indirect 
allorecognition, where polymorphic donor-derived peptides are presented for recipient T 
cells, and the other is direct allorecognition, where polymorphic variants of donor MHC are 
recognized by recipient T cells. The latter is by far the strongest and because MHC is 
extremely polymorphic, this mechanism constitutes a major hurdle for allogeneic stem cell 
transplantation (Afzali et al., 2008; Gökmen et al. 2008; Hornick, 2006; Ingulli, 2010). 
T-cell activation is dependent on binding of antigen-presenting MHC class I (signal 1) and 
non-antigen-specific co-stimulatory molecules CD40, CD80 and CD86 expressed by donor 
cells to their ligands on T cells (signal 2)(Jenkins, 1994). Presentation of peptides by MHC 
class I to TcR in the absence of co-stimulation induces anergy or apoptosis of T cells, 
abortive proliferation or tolerance-inducing immunoregulation (Ford & Larsen, 2009; Pearl 
et al., 2011). 
Two types of T cells, cytotoxic and regulatory, have been implicated in immune responses in 
general and in relation to stem cell transplantation. Cytotoxic or cytolytic T cells (CTL or TC) 
are activated T lymphocytes (usually CD8 positive) that can induce the killing of target cells, 
be it infected or allogeneic cells. CTL can induce apoptosis of targets cells by two 
independent mechanisms: release of cytotoxins such as perforin, granzymes and granulysin, 
or by binding of FasL (CD95L) to Fas (CD95) molecules expressed on the target cell (Brown, 
2010). 
Regulatory T cells (Treg) comprise several specialized subsets of T cells that are able to 
control immune responses and promote and maintain immune tolerance in an antigen-
specific way. Presence of Treg has been associated with tolerance whereas their deficiency or 
defective function has been correlated with autoimmunity in many experimental models 
(Roncarolo et al., 2011). 
The degree of histocompatibility at the HLA-locus can be determined by serologic or 
genomic tissue typing. In case of discrepancy for HLA class II antigens, the resulting 
incompatibility may be measured through Mixed Lymphocyte Reactions (MLR). Peripheral 
blood mononuclear cells (PBMC) from two different individuals (HLA mismatched 
allogeneic setting) are co-cultured for 4-6 days. One of the cell populations (stimulators) is 
irradiated to avoid its proliferation. The non-irradiated cells (responders) will start 
proliferating due to direct allorecognition, and this is measured through uptake of 3H-
(tritiated) thymidine. Suppression of T cell proliferation is often measured by adding 
unmodified or modified stem cells to the MLR (Aggarwal & Pittenger, 2005; Le Blanc et al., 
2003a; Wonderlich et al., 2006).  
MHC class II molecules and co-stimulatory molecules are primarily expressed on 
professional antigen-presenting cells (APC) such as B cells, monocytes and dendritic cells. 
MHC class II consists of three classes of HLA-II antigens: HLA-DP, -DQ and -DR presenting 
peptide antigens derived from extracellular proteins to CD4+ T helper cells to elicit an 
immune response. Because MHC class II expression is cell-type specific and mainly 
restricted to thymic epithelial cells and bone marrow-derived antigen presenting cells it is 
not expected to be a problem in many stem cell applications (Handunnetthi et al., 2010). 
Natural killer (NK) cells participate in the innate immune response as they are capable of 
killing tumor cells and virally-infected cells. NK cells express a large number of cell surface 
receptors named Killer-cell Immunoglobulin-like Receptors (KIR) and NKG2 (CD94) that 
have classical and non-classical class I antigens as their ligands , respectively, and deliver 
either activating or inhibitory signals. The relative balance of these signals regulates NK cell 
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activity (Orr & Lanier, 2010) and absence of HLA class-I expression therefore may lead to 
killing by NK cells. This is of relevance for stem cell therapy because some stem cells lack 
classical HLA class I expression all together and because more differentiated cells may fail to 
express alleles recognized by the NK cells of the recipient. 
Organ transplantation is a routine therapeutic strategy for patients with end-stage organ 
failure (Newell, 2011) and bone marrow-derived hematopoietic stem cells are used to treat 
several hematopoietic malignancies and rare immunodeficiencies (Nehlin & Barington, 
2009). Clinical experience through more than three decades with these treatments clearly 
demonstrates the relevance of both T cells and NK cells in transplantation.  Allogeneic 
transplantation of organs often results in the development of either a) graft-versus-host-
disease (GvHD) or b) immune rejection. GvHD is a condition where donor cells within a 
transplant launch an immune reaction against the recipient cells (Menendez et al., 2005; 
Shlomchik, 2007). The host can also build an acute and/or chronic rejection against antigens 
perceived as non-self by the recipient’s immune system leading to destruction of the graft. 
Those antigens can belong to MHC, minor histocompatibility complex (mHC) or AB0 blood 
groups (Bradley et al., 2002; Charron et al. 2009; Feng et al., 2008; Shlomchik, 2007; Spencer 
et al., 2010). 
3. Immunological tolerance at the fetal-maternal interface 
A classical example of immune tolerance is found during pregnancy. The maternal immune 
system allows for the successful development of a semi-allograft consisting of a fetus and a 
placenta that express both maternal (self) and paternal (non-self) antigens. Cytotoxic 
adaptive immune responses are diminished, bypassed, or even abrogated (Leber et al., 
2010). Immunological processes such as innate immunity remain intact to continue to 
provide host defense against infection and to interact with fetal tissues to promote 
successful placentation and pregnancy. 
The trophoblasts are the cells that form the outer layer of the blastocyst, that develop into a 
large part of the placenta, and have a crucial role in the implantation of the developing 
embryo by interactions with the decidua, the lining of the maternal uterus containing 
endometrial stromal cells. The placenta and fetal trophoblast cells are directly exposed to 
maternal blood and tissues. The trophoblast layer protects the inner cell mass (ICM) from 
attack by cytotoxic components of the maternal immune system dedicated to destroying 
foreign tissues. The inner cell mass consists of a group of cells inside the primordial embryo 
that will eventually develop into defined fetal structures (Mor & Abrahams, 2009). 
In humans, trophoblast cells differentiate from the trophoblast shell that surrounds the post-
implantation embryo into two main lineages, villous trophoblast and extravillous 
trophoblast. Primary villous trophoblast cells do not express β2-microglobulin or any HLA 
class I or HLA class II molecules,  whereas extravillous trophoblast cells express HLA-C, 
HLA-G and HLA-E, but not HLA-A, HLA-B or HLA-DR molecules in a normal pregnancy. 
Villous trophoblasts are in contact with the systemic immune system, whereas extravillous 
trophoblasts interact with the local mucosal immune cells. When extravillous trophoblasts 
were exposed to interferon-gamma (IFN-γ), a pro-inflammatory cytokine, they could not 
induce the expression of HLA-A, -B, -DR or up-regulate significantly HLA-G (Apps et al., 
2009). A comprehensive overview of MHC expression at the fetal-maternal interface was 
recently reported (Tilburgs et al., 2010). 
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Human embryonic tissues possess a range of proteins and mechanisms that efficiently 
counteract and prevent maternal cytotoxic T cell attack and thereby provide protection and 
immune privilege to the fetus (Clark, 2005; Fändrich, 2002; Mor & Abrahams, 2009; Parhar et 
al. 1989; Petroff & Perchellet, 2010; Rebmann et al., 2010; Rizzo et al., 2011a; Verloes et al., 
2011). 
Knowledge of the immunological tolerance mechanisms taking place at the feto-maternal 
interface in mouse and rat models have contributed to extend such findings to human cells. 
Attention has focused on a group of pluripotent stem cells known as human embryonic 
stem cells (hESC), derived from the ICM of 6-8 days pre-implantation blastocysts obtained 
from in vitro fertilization procedures (Thomson et al., 1998), because they could potentially 
be used in cell therapy and regenerative medicine (Figure 1; Nehlin & Barington, 2009). 
However, the use of hESC may be limited by immunological incompatibility between the 
donor and the recipient as explained in the next sections. 
4. Immunogenicity of human embryonic, multipotent and reprogrammed 
stem cells 
4.1 General considerations 
Ever since the development of the techniques that allowed researchers to establish 
blastocyst-derived hESC, there has been a great deal of interest in their potential use in 
regenerative medicine (Thomson et al., 1998). To satisfy clinical requirements, a number of 
matters need to be addressed including 1) the precise control of differentiation towards the 
tissue or cell-type of choice without remnant undifferentiated hESC; 2) safety issues 
pertaining the risk of  transplanting undifferentiated hESC cells that could result in teratoma 
formation, the possible presence of genetic modifications as a result of ex-vivo culture, and 
immunogenicity concerns (see below); 3) the development of xenogeneic-free culture 
conditions and 4) potential ethical conflicts (Nehlin & Barington, 2009; section 6.1).  
In-depth studies of the molecules and mechanisms responsible for the low grade of 
immunogenicity and allograft tolerance of cultured hESC in non-histocompatible recipients 
have been relatively few compared with bone marrow stem cell studies (section 4.3). The 
immune-privileged status of hESC resembles the tolerance properties exhibited by the 
developing embryo in the feto-maternal interface (section 3; English & Wood, 2011; 
Grinnemo et al., 2008a; Menendez et al., 2005). In comparison, multipotent stem cells such as 
bone marrow stromal cells still retain immune-privileged properties even after further 
differentiation (Le Blanc & Pittenger, 2005).  
 
 
Fig. 1. Early differentiation of hESC 
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Phase contrast photographs of hESC KMEB2 (Harkness et al., 2010) growing on feeder-free 
Matrigel in an undifferentiated state (day 0), followed by differentiation towards embryoid 
body formation at days 1, 5 and 20 (left to right panels). Magnification: 100x 
Traditionally, hESC have been isolated from the ICM of the blastocyst stage of the early 
developing embryo (Thomson et al., 1998). Also, in recent years, donor-specific hESC were 
obtained from single blastomeres at the 8-cell stage of embryogenesis or generated by 
somatic cell nuclear transfer (SCNT). Pluripotent stem cells with features resembling the 
hESC state have been generated by parthenogenetic activation of unfertilized oocytes and 
genetic reprogramming (Jopling et al. 2011; Nehlin & Barington, 2009; Yamanaka & Blau, 
2010). The immunological aspects regarding hESC and hESC-like pluripotent stem cells are 
addressed below. 
4.2 MHC class I expression in human embryonic stem cells, early stem cell 
progenitors and induced pluripotent stem cells 
4.2.1 Expression studies 
Immunogenicity concerns focus on the presentation of antigens and expression of MHC 
class I proteins, as well as expression of molecules that make hESC potential targets of 
cytotoxic responses by T and NK cells. 
Almost all cellular studies dealing with HLA class I expression have relied on a single 
antibody (W6/32) targeting simultaneously HLA-A, -B, -C and cross-reacting with HLA-E 
and –F (Uchanska-Ziegler & Ziegler, 2007). Indirect immunofluorescence assays showed 
that human pre-implanted embryos expressed neither HLA class I, II antigens nor β2-
microglobulin (Desoye et al., 1988). However, a later study using immunocytochemistry 
showed expression of HLA-G and MHC class I (Jurisicova et al., 1996). The status of 
expression of several immunogenicity markers on the surface of several hESC lines was later 
semi-quantified by flow cytometry: MHC class I proteins were expressed at very low levels, 
and increased moderately upon in vitro or in vivo differentiation. However, no cell surface 
staining of HLA-G or MHC class II was apparent in undifferentiated or differentiated hESC.  
Treatment of hESC in vitro with IFN-γ, a cytokine secreted during the course of an immune 
response, resulted in high-level expression of MHC class I (Drukker et al., 2002; Grinnemo et 
al., 2006). Another study showed that hESC express both MHC class I and β2-microglobulin 
at low levels on the cell surface regardless of using mouse feeder cells or feeder-free 
cultures. Upon IFN-γ stimulation, both MHC class I and β2-microglobulin were strongly up-
regulated and this effect was considerably enhanced after cells had been pre-treated with 
retinoic acid, a differentiation stimulator (Draper et al., 2002). 
The low rate of MHC class I expression was explained by the low expression of components 
of the antigen-processing machinery (APM) such as β2-microglobulin and tapasin, without 
detectable expression of TAP1, TAP2, LMP2, and LMP7 (Cabrera et al., 2007; Suarez-Alvarez 
et al., 2010). 
Few studies exist where human MHC class I expression is followed during the 
differentiation process. Recently, an extensive study showed that hESC-derived embryoid 
bodies displayed significantly higher expression of HLA-B, HLA-E,–F and β2-microglobulin 
compared to the undifferentiated cells. Expression of NK cell receptor NKG2D ligands 
(MICA, MICB) was evident in all undifferentiated pluripotent stem cells lines analyzed, and 
their expression was maintained after differentiation. MHC expression was subject to 
epigenetic control in hESC. It was shown that methylation of histone H3K9me3 repressed 
the tapasin gene in undifferentiated cells whilst HLA-B and β2m acquired the histone 
 
Stem Cells in Clinic and Research 110 
H3K4me3 modification during the differentiation to embryoid bodies. Absence of HLA-DR 
and HLA-G expression was regulated by DNA methylation (Suarez-Alvarez et al., 2010). 
The expression of the HLA-A allele A*02 was found to be moderate in hemangioblasts or 
hematoendothelial precursors derived from hESC cell line H9, that exist transiently in early 
embryonic development, and express markers of immature hematopoietic and endothelial 
cells (CD31, CD34, VE-cadherin, Flt-1) and mature differentiated cells (CD45, CD33, CD146). 
However, HLA-A02* expression increased dramatically as cells were differentiated into 
endothelial or hematopoietic stem cells (Basak et al., 2009). Differential regulation of HLA-
A,-B,-C alleles in multipotent stem cells has been revealed (Isa et al., 2010; section 4.3) and 
similar findings have been evaluated in embryonic and early hematopoietic precursors 
(Sabir et al., in preparation). 
hESC can not only be obtained from the inner cell mass of day 5-6 developing embryos, or 
earlier, but can also be generated by SCNT, parthenogenesis, or by reprogramming adult 
somatic cells to generate inducible pluripotent stem cells (iPS cells; Jopling et al., 2011; 
Nehlin & Barington, 2009; Yamanaka & Blau, 2010). Parthenote-derived hESC show 
equivalent phenotypes to hESC in the undifferentiated state and can differentiate as 
demanded, but no data on the expression of molecules conferring immunogenicity is yet 
known (Harness et al., 2011), and is also unknown for SCNT-derived hESC.  
Reprogrammed iPS cells resemble hESC in many ways, with their capacity of self-renewal, 
and pluripotency state. One of their main features is that they can be obtained from 
essentially any somatic, fully differentiated adult cells and converted to pseudo-hESC from 
which one can derive cells and tissues that are genetically compatible with the donor of the 
original cells. Such strategy, although seemingly expensive, could represent a favorable 
method to avoid any kind of immunological rejection. Thus, exponential interest in 
generating such cells has led to characterize the expression of various immunogenicity-
associated molecules. Of particular interest, HLA-B, -C, -E, and β2-microglobulin mRNA 
levels were reduced in iPS cells compared to parental fibroblasts, whereas HLA-A, -G and 
MHC class II expression was absent. The mRNA levels of APM components TAP-1, TPN, 
LMP2 and RFX5 plummeted during the reprogramming process to iPS (Suarez-Alvarez et 
al., 2010). 
However, a recent report showed that expression of MHC class I in iPS cells by flow 
cytometry is slightly higher in reprogrammed undifferentiated hESC than in ICM-derived 
hESC (Pearl et al., 2011). It is unclear if such difference would account for immunological 
discordance taking into account that iPS cells are expected to be histocompatible since the 
donor and recipient of iPS cells is the same individual. A drawback is represented by the 
genetic tools used to reprogram somatic cells to iPS cells, because they could raise 
immunogenicity concerns (Nehlin & Barington, 2009; Yamanaka & Blau, 2010). 
4.2.2 Cellular and immunological studies 
hESC underwent minimal killings when incubated with NK cells. NK cytotoxicity is 
mediated by engagement of NK lysis receptors, NKp30, NKp44, NKp46, and CD16. All of 
their ligands, except the NKp44 ligand, were absent on hESC and were not induced after 
IFN-γ treatment (Drukker et al., 2002). 
Undifferentiated hESC were shown to possess immune-privileged characteristics and when 
transplanted into immune-competent mice, they did not elicit an immune response. 
Moreover, the inhibitory effect of hESC on alloreactive T cells was mediated by direct cell 
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membrane interactions rather than by secreted factors. Even slightly differentiated hESC-
derived progenitors within cell aggregates known as embryoid bodies (Figure 1), did not 
induce proliferation of allogeneic T cells (Li et al., 2004). In contrast, a more recent study 
found that cellular extracts from hESC could indeed retain the immunoregulatory properties 
of intact cells e.g. inhibiting the function and maturation of monocyte-derived dendritic cells 
(Mohib et al., 2010).  
In xenotransplantation and allotransplantation settings, when hESC were transplanted into 
various strains of immunocompetent mice and monitored during one month, the cells were 
totally eliminated (Drukker et al., 2006). In contrast, when a hESC-derived graft was 
transplanted into immune deficient mice lacking T, B or NK cells, it was found that T-cell 
deficient animals failed to reject the hESC-derived graft.  The lack of NK cells or B cells did 
not interfere with vigorous hESC rejection, indicating that T cells play a pivotal role in hESC 
immune rejection. MHC class I molecules were expressed at low levels while MHC class II, 
and co-stimulatory proteins CD80 and CD86 were not expressed. The low 
immunostimulatory capacity of hESC was verified by transplanting undifferentiated or 
differentiated hESC into a mouse model, in which mice were pre-conditioned to carry 
PBMC from human origin. After one month, only a minute alloresponse was observed while 
control adult grafts were totally rejected. If MHC class I expression was induced, an increase 
in the alloresponse took place. These findings suggested that the use of 
immunosuppressants could be reduced in the case of hESC-derived transplants compared to 
solid organ transplantions (Drukker et al., 2006).  
hESC-derived cells were found to be capable of long-term hematopoietic engraftment when 
transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice 
(Tian et al., 2006). hESC were shown to be immunologically inert when transplanted into the 
myocardium of immunocompetent mice and did not inhibit immune responses judged by an 
increase in lymphocyte infiltration with positive histological staining for CD11b, CD3, CD4 
and CD8 during direct or indirect antigen presentation, and they were acutely rejected in a 
xenogeneic setting (Grinnemo et al., 2006), similar to previous findings (Drukker et al., 2006). 
The earlier interpretations that hESC are immune privileged were contradicted by a new 
study whereby the fate of transplanted hESC were traced by bioluminescent imaging in 
immune-competent host mice. Graft infiltration by host immune cells occurred within 5 
days, and already after 10 days, there was no evidence of hESC left. When hESC were 
transplanted into immune-deficient (NOD/SCID) host mice, the transplants expanded in 
number after only 10 days and teratoma formation was evident at 42 days. Rejection was 
demonstrated to be mediated predominantly by CD4+T cells and it was delayed when 
immunosuppressive therapies commonly used in the clinic were applied, such as tacrolimus 
and sirolimus (Swijnenburg et al., 2008).  
Individual hESC may survive allotransplantation due to low immunogenicity compared to 
mature, adult cells, thereby escaping from NK cell- or T cell-mediated cytotoxicity. 
However, during differentiation MHC class I expression often increases and the presence of 
certain cytokines such as interferons may strongly induce its expression. In such cases, 
antigen disparities between donor hESC and recipient cells will lead to rejection, unless 
prevented (section 6.1). Alloreactive T cells are the major effectors of graft rejection and 
these cells usually prevent the generation of teratomas in immunocompetent animals 
injected with allogeneic ESC. 
Recently, the immunogenicity of inducible pluripotent stem (iPS) cells was examined in the 
mouse model. In contrast to derivatives of mouse embryonic stem cells, abnormal gene 
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expression in some cells differentiated from iPSC could induce T-cell-dependent immune 
responses in syngeneic recipients. Therefore, the immunogenicity of patient-specific iPS cells 
should be evaluated before any clinic application of these autologous cells into the patients 
(Zhao et al., 2011). 
One of the factors used in reprogramming procedures towards generating iPS cells is OCT4, 
a transcription factor that plays a key role in the pluripotency program. Most healthy 
individuals harbor OCT4-specific CD4+ memory T cells indicating a lack of immune 
tolerance to this antigen (Dhodapkar et al., 2010). 
4.3 MHC class I expression in human multipotent mesenchymal stem cells 
Human mesenchymal stem cells (hMSC) are multipotent stem cells with a fibroblast-like 
morphology and the capacity to self-renew in vivo that are distributed across virtually every 
tissue in the body. The “potency” of such cells is not restricted to skeletal tissues (bone, 
cartilage, fibrous tissue, fat, and myelosupportive stroma) but also includes non-skeletal 
mesodermal derivatives such as heart, endothelial cells and striated muscle. In contrast, 
osteogenic, stromal, or skeletal stem cells are multipotent CD146+ cells found in the bone 
marrow stroma that can differentiate into bone, cartilage, fibrous tissue, adipose tissue, and 
myelosupportive stroma but not to skeletal muscle, other mesoderm-derived tissues, and 
non-mesodermally derived tissues (Figure 2; Bianco et al., 2010; Nombela-Arrieta et al., 
2011). 
 
 
Fig. 2. Phase contrast photograph of a human bone marrow-derived stromal cell (hMSC). 
Magnification: 100x 
Recently, CD146 expression was shown to differentiate between perivascular versus 
endosteal localization of non-hematopoietic bone marrow stem cell populations and this 
localization correlated with CD146 being expressed during normal oxygen conditions 
(normoxia) and absent during hypoxia (Tormin et al., 2011).  
hMSC are an attractive source of stem cells for use in tissue engineering such as bone 
regeneration and cartilage repair, due to their differentiation capacity, their relative 
availability and their immune privilege properties (section 6.2; Niemeyer et al., 2006; 
Nombela-Arrieta et al., 2011). 
An early study described the presence of various immunologically relevant markers such as 
neutral endopeptidase CD10, aminopeptidase CD13, neural cell adhesion molecule CD56, a 
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typical NK cell marker, and MHC class I in hMSC isolated from fetal, mature, and geriatric 
individuals (Young et al. 1999). In another study, hMSC isolated from the bone marrow 
stroma were also shown to constitutively express MHC class I and even lymphocyte 
function-associated antigen (LFA)-3 antigens whereas MHC class II and intercellular 
adhesion molecule (ICAM)-1 antigens were only expressed upon IFN-γ treatment and CD80, 
CD86, or CD40 co-stimulatory molecules were not expressed at all. Moreover, hMSC failed 
to stimulate allogeneic PBMC or T-cell proliferation in mixed lymphocyte reactions (Tse et 
al., 2003).   
In yet another study, undifferentiated hMSC were shown to express significant levels of 
MHC class I expression and no MHC class II expression, and when hMSC were 
differentiated into adipocytes, osteoblasts, and chondrocytes, they were shown to express 
lower levels of MHC class I, but still not MHC class II. Both undifferentiated hMSC and 
differentiated hMSC were not immunogenic as they did not stimulate allogeneic 
lymphocytes in co-culture experiments. Upon IFN-γ treatment, MHC class II expression 
increased dramatically in hMSC, but despite this, the inhibitory effect on lymphocyte 
alloreactivity persisted (Le Blanc et al., 2003b). Several terminally differentiated cell types 
like neurons, hepatocytes, skeletal and cardiac muscle cells failed to constitutively express 
HLA class I (Fleming et al., 1981). 
hMSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL 
with a limited efficiency, likely because of some defects in APM components such as lack of 
expression of LMP7, LMP10, and ERp57. However, they are protected from CTL-mediated 
lysis through a mechanism that is partly sHLA-G-dependent (see section 5.2.2.3; Morandi et 
al., 2008). 
While hESC and the inner cell mass in blastocysts have been shown to express very low 
levels of HLA class I, lineage-committed stem cells like mesenchymal stem cells (MSC) have 
a much higher expression similar to that of lymphocytes. Constitutive expression of HLA 
class I is largely restricted to cells of the lymphoid organs, the epithelia and the lining of 
small vessels. HLA-A, -B- and -C are equally expressed in blood leukocytes and regulated 
primarily at the level of transcription through promoter elements that are conserved among 
the HLA genes. Using quantitative multicolour flow cytometry and allele-specific antibodies 
targeting classical MHC class I on muscle satellite cells, bone marrow stromal cells and 
adipose-derived stem cells, as well as in PBMC, we found high cell-surface expression of 
HLA-A whereas HLA-B and -C alleles were strongly down-regulated. IFN-γ stimulation of 
stem cells during 48-72h was required to induce full HLA-B protein expression. The major 
contributor to repression of HLA-B and -C in stem cells during basal, non-induced 
conditions may be a post-transcriptional mechanism leading to translational attenuation in 
stem cells. Since different HLA alleles have variable affinities for intracellularly-generated 
peptides, the lack of HLA-B and -C expression can influence antigen presentation and the 
resulting immune response (Isa et al., 2010). 
5. Immune-modulating properties 
5.1 Immune-modulating properties of human embryonic stem cells 
As explained previously in section 3, embryonic tissues are endowed with powerful 
immune-protecting mechanisms. However, relatively little is known about molecules 
expressed by hESC of the ICM exerting immune tolerance functions, especially considering 
that such intrinsic hESC properties could perhaps be used in regenerative transplantation 
protocols. 
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hESC have limited antigen presentation capacity because of low MHC class I cell surface 
expression levels and the complete lack of MHC class II molecules and co-stimulatory 
molecules (Drukker et al., 2006; Grinnemo et al., 2006).  
Among known immune tolerance molecules (section 5.2), ICM-derived hESC expressed the 
tolerogenic HLA-G molecule at the mRNA and protein levels, but it underwent down-
regulation in ICM cells during blastocyst growth (Rizzo et al., 2011a; Verloes et al., 2011). 
Several immune-modulating proteins found in hMSC are also expressed in hESC (section 
5.2; Nehlin et al., Isa et al.; Sabir et al., in preparation). 
5.2 Immune-modulating properties of human mesenchymal stem cells 
hMSC are capable of down-regulating allogeneic immune responses by a number of 
strategies that are illustrated in Figure 3. These strategies will be explained in detail below. 
Immunosuppression by MSC is species-specific, indicating that the valuable contributions 
from mouse studies in this area cannot necessarily be extrapolated to the human scenario 
(Ren et al. 2009). Thus, here we will explore the most relevant findings in the field of hMSC-
mediated immunosuppression that have recently gained much attention. 
 
 
 
Fig. 3. Illustration depicting the main immune-modulating properties of human 
mesenchymal stem cells. 
hMSC exhibit potent immune-modulating properties which could be useful in numerous 
clinical applications (section 6.2; Barry et al., 2005; English et al., 2010; Hoogduijn et al., 2010; 
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Le Blanc & Pittenger, 2005; Nauta & Fibbe, 2007; Rasmusson, 2006; Siegel et al., 2009; 
Sotiropoulou & Papamichail, et al., 2007; Trento & Dazzi, 2010). The immunomodulatory 
properties of MSC derived from adult human tissues including bone marrow (BM), adipose 
tissues (AT), umbilical cord blood (CB), and cord Wharton's jelly (WJ) were shown to be 
comparable (Yoo et al., 2009; Najar et al., 2010). CD4+ and CD8+ T-lymphocytes were 
equally targeted by hMSC of different origins, and the effects included prevention of 
lymphocyte activation as well as the suppression of T-cell proliferation regardless of the 
stimuli used to activate the lymphocytes (Najar et al., 2010). 
Many different pathways mediating hMSC immunotolerance have been suggested such as 
suppression of T and B cell proliferation both by cell-mediated and soluble factors (Siegel et 
al., 2009; Uccelli et al., 2008). 
Multiple cell-cell interactions and the secretion of soluble factors determine the grade of 
immunomodulatory capacity by hMSC. Adapted from Aggarwal & Pittenger 2005; Barry et 
al. 2005; Le Blanc & Ringden, 2007;  Nasef et al., 2008; Nauta & Fibbe, 2007; Nemeth et al., 
2009; Rasmusson, 2006; Uccelli et al. 2008, and many references in the text. 
5.2.1 Origins of the hMSC immunosuppression: cell-cell interactions 
Multiple interactions take place between hMSC and cells of the innate and adaptive immune 
system (Uccelli et al., 2008; Shi et al. 2011). The co-culture of hMSC with purified blood 
subpopulations in mixed lymphocyte reactions (MLR)(see section 3) has yielded valuable 
information as regards to hMSC-mediated immuno-modulatory mechanisms of action. 
Several studies have explored the effect of hMSC on T cell populations. An early report 
indicated that hMSC were capable of inhibiting allogeneic T cell responses in vitro 
(Klyushnenkova et al., 1998). Autologous or allogeneic hMSC strongly suppressed T-
lymphocyte proliferation, without induction of apoptosis, by both cellular as well as non-
specific mitogenic stimuli and was likely due to the production of soluble factors (Di Nicola 
et al., 2002). 
An in-depth analysis was later carried out by Rasmusson et al., 2003, where it was shown 
that hMSC inhibit T cells in the early activating phase of the allograft reaction, but not in the 
effector phase. When hMSC were added early in the MLR, they inhibited cytotoxicity, 
presumably by preventing the formation of active CTL. When MSC were added on day 3 to 
the 6-day MLR, little effect on cytotoxicity was observed, indicating that hMSC did not 
appear to inhibit activated CTL and even NK cells (Rasmusson et al., 2003). 
Proliferation of allogeneic CD3+ T cell populations was suppressed by hMSC, in a dose-
dependent, genetically unrestricted manner, regardless of being pre-treated or not with IFN-
γ (Klyushnenkova et al., 2005). hMSC suppressed the proliferation of both CD4+ and CD8+ 
T lymphocytes, as well as of NK cells. The suppressive activity of hMSC was not only cell-
contact dependent but required further the presence of IFN-γ produced by activated T cells 
and NK cells (Krampera et al., 2006; Pradier et al., 2011).  
hMSC altered as well the cytokine secretion profile of naive and effector T cells: T helper 1 
(Th1) and 2 (Th2), and NK cells to induce a more anti-inflammatory or tolerant phenotype, 
increased the proportion of Treg and decreased the secretion of IFN-γ from NK cells induced 
by IL-2 (Aggarwal & Pittenger, 2005).  
hMSC inhibited T-cell proliferation triggered either by allogeneic, mitogenic or antigen-
specific stimuli. Interestingly, hMSC inhibited T-cell proliferation by inducing apoptosis 
once T cells were CD3-mitogenically activated, but had no effect on resting T cells (Plumas 
et al., 2005). hMSC were able to inhibit proliferation of not only resting thymocytes but also 
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dividing thymocytes cultured in the absence of trophic factors. hMSC could support T cell 
survival in a quiescent G0 state without inducing apoptosis, but T cells still regained their 
activation capacity once immunosuppression was not longer present. These results 
suggested that hMSC are endowed with the intrinsic capacity of promoting survival of T 
cells in a resting state. The protective effect of hMSC targets mainly the “death receptor” 
pathway of apoptosis, as suggested by the down-regulation of Fas receptor and Fas ligand 
on TCR activated T cells (Benvenuto et al., 2007). 
hMSC were shown to target T-cell proliferation but not their effector function (cytotoxicity). 
This could be explained by inducing T cells to the G0/G1 cell cycle phase, in part through 
inhibition of cyclin D expression and up-regulation of p27kip1 (Giuliani et al., 2011; 
Ramasamy et al., 2008; Siegel et al., 2009). According to a recent study, T cell inhibition by 
hMSC was not due to the soluble HLA-G5 isoform, but to the surface expression of HLA-G1, 
as shown by the need of cell-cell contact and by the use of neutralizing anti-HLA-G 
antibodies (Giuliani et al., 2011; section 5.2.2.3). 
hMSC down-regulated alloantigen-induced lymphocyte expansion, especially that of 
CD8+T cells and of NK lymphocytes, decreased in a dose-dependent manner alloantigen-
specific cytotoxic capacity mediated by either CTL or NK cells and favoured the 
differentiation of regulatory/suppressive CD4+ T-cell subsets co-expressing CD25 and/or 
CTLA4.  More effective suppressive activity on MLR-induced T-cell activation was observed 
when hMSC were used as third-party, rather than autologous, with respect to MLR-
responder cells. These findings support the use of MSC to prevent immune complications 
related to both hematopoietic stem cell and solid organ transplantation and to the theory 
that hMSC are universal suppressors of immune reactivity (Maccario et al., 2005; Spaggiari 
et al. 2009). 
Another report showed that the immunosuppressive effect of hMSC targets T cell 
proliferation of different subpopulations but their effector function or cytotoxicity was not 
affected in the presence of hMSC at different ratios (Ramasamy et al., 2008). 
The significance of the hMSC:T or hMSC:NK co-culture ratios has been investigated in MLR. 
At low concentrations, hMSC supported rather than inhibited mitogen-stimulated PBMC. 
Higher concentrations of hMSC not only suppressed alloreactive effector cells, but greatly 
reduced lymphocyte proliferation caused by potent T-cell mitogens, in autologous or 
allogeneic PBMC, meaning that the responses were independent of MHC (Le Blanc et al., 
2003a). Consistent with this early study, using purified CD3+ T cells only, hMSC were 
shown to allow T-cell proliferation at a lower MSC:T-cell ratio (1:40) whereas an optimal 
inhibitory effect was shown when the target (hMSC): effector (T cell) ratio was 1:4 or 1:8 
(Najar et al., 2009). 
IL-15–stimulated NK cells from 4-day co-culture with hMSC were tested in cytotoxicity 
assays. When the hMSC:NK cell ratio was low (up to 1:10), hMSC altered the phenotype of 
NK cells and suppressed their proliferation, cytokine secretion, and cytotoxic capacity 
against T-cell specific peptide-HLA class I-complexes presented on cancer cells 
(Sotiropoulou et al., 2006). Some of these effects required cell-to-cell contact, whereas others 
were mediated by soluble factors (see below), suggesting the existence of diverse 
mechanisms for MSC-mediated NK cell suppression. On the other hand, hMSC from HLA-
mismatched individuals are susceptible to lysis by activated NK cells (Selmani et al., 2009; 
Sotiropoulou et al., 2006). 
Ex vivo-isolated human NK cells become activated upon interaction with bone marrow 
stromal cells, releasing high amounts of IFN-γ and TNF-α cytokines. These effects depend 
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on the LFA1/ICAM1 interaction and the NKp30 receptor (Poggi et al., 2005). hMSC 
inhibited the surface expression of NKp30 and NKG2D activating NK receptors that are 
involved in NK-cell activation and target cell killing, and no cell surface expression of the 
NKp44 activating receptor (absent in resting NK cells and expressed upon cell activation) 
occurred in NK cells cultured with hMSC (Spaggiari et al., 2008). 
The effects of hMSC on monocytes and dendritic cells were also examined. hMSC could 
suppress CD14+ monocyte differentiation into dendritic cells (DC), the most potent antigen-
presenting cells (APC)(Jiang et al., 2005), as well as maturation of APC (Beyth et al., 2005) 
and altered the cytokine secretion profile of dendritic cells (Aggarwal & Pittenger, 2005). 
Mature DC treated with hMSC decreased expression of antigen-presenting and co-
stimulatory molecules, and down-regulated IL-12 secretion (Jiang et al., 2005). Similar 
results were shown where hMSC strongly inhibited the differentiation of alloantigen-
induced monocytes to immature dendritic cells (DC1)(Maccario et al., 2005). 
Allogeneic hMSC did not affect B lymphocyte proliferation during allo-stimulation with 
PBMC in mixed lymphocyte cultures at the the B-cell/hMSC ratio of 1:10 (Krampera et al., 
2006). However, another study reported that hMSC inhibited B-cell proliferation by 
induction of cell cycle arrest at the G0/G1 phase. The differences were likely due to the cell 
ratios used, where maximum inhibition of B-cell proliferation was observed at the B-
cell/hMSC ratio of 1:1, detected at a 1:2 ratio and non-measurable at 1:5 and 1:10 ratios. 
Also, hMSC inhibited B-cell differentiation because IgM, IgG, and IgA production was 
significantly impaired. CXCR4, CXCR5, and CCR7 B-cell expression, as well as chemotaxis 
to CXCL12, the CXCR4 ligand, and CXCL13, the CXCR5 ligand, were significantly down-
regulated by hMSC, suggesting that these cells affect the chemotactic properties of B cells. B-
cell co-stimulatory molecule expression and cytokine production were unaffected by hMSC 
(Corcione et al., 2006). hMSC were able to suppress allo-specific antibody production in 
vitro, and may therefore help overcome a positive cross-match in sensitized transplant 
recipients (Comoli et al., 2008). 
hMSC also inhibited invariant Natural Killer T (iNKT) and γδ T cell expansion from 
peripheral blood mononuclear cells. Such inhibition was neutralized by indomethacin, a 
non-steroid anti-inflammatory drug that inhibits the function of the prostaglandin E2 
molecule (see below, section 5.2.2). iNKT and γδ T have protective and regulatory immune 
functions in common because they are involved in defense against infectious organisms, 
tumor rejection, autoimmune disease pathogenesis, and maintenance of transplant tolerance 
(Prigione et al., 2009). 
hMSC have also been shown to influence human polymorphonuclear neutrophil (PMN) 
responses in co-culture experiments, exerting anti-apoptotic effects that sustained and 
amplified the functions of PMN in response to toll-like receptors TLR3- and TLR4-
triggering, that may consequently contribute to inflammatory disorders. The biological 
effects exerted on PMN by TLR3-activated bone marrow-derived hMSC are mediated by the 
combined action of interleukin 6, interferon-β (IFN-β), and granulocyte macrophage colony-
stimulating factor (GM-CSF), while those exerted by TLR4-activated BM-MSC mostly 
depend on GM-CSF (Cassatella et al., 2011). The key hMSC-derived soluble factor 
responsible for neutrophil protection from apoptosis was IL-6, (Raffaghello et al., 2008; see 
section 5.2.2.4). 
Finally, an interesting study showed that the Stro-1-enriched population of hMSC isolated 
from the bone marrow elicits a significantly (~10 times) more profound dose-dependent 
inhibition of lymphocyte proliferation in mixed lymphocyte reactions than hMSC in general, 
suggesting its use in allogeneic transplantation (Nasef et al., 2009). 
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5.2.2 Origins of the hMSC immunosuppression: secreted factors 
Even though the presence of hMSC in mixed lymphocyte cultures elicits stronger 
immunosuppressive effects than only hMSC-free culture supernatants, evidence suggests 
that secreted factors released to the media might account for a significant part of the hMSC-
derived immunosuppression (Najar et al., 2009; Nasef et al., 2008a; Rasmusson et al. 2003). 
Soluble immunomodulatory factors such as indoleamine 2,3-dioxygenase (IDO), 
prostaglandin E2 (PGE2), sHLA-G, transforming growth factor (TGF-β), interleukins IL-1β, 
IL-6, IL-8, IL-10, IL-11, hepatocyte growth factor (HGF), IFN-γ, stromal cell-derived factor-1 
(SDF-1) are all secreted by hMSC (Di Nicola et al., 2002; Barry et al., 2005; Giuliani et al., 
2011; Najar et al., 2009; Nasef et al., 2008a; Wu et al., 2010). 
Secretion of pro-inflammatory and anti-inflammatory cytokines, chemokines, growth factors 
and prostaglandins by hMSC under resting and inflammatory conditions has been 
investigated (Hoogduijn et al., 2010; Wu et al., 2010). Exposure of hMSC to pro-
inflammatory cytokines such as IFN-γ, tumour necrosis factor (TNF)-α and interleukin (IL)-6 
enhances the immunosuppressive capacity of hMSC, suggesting that the use of pre-
conditioning to pro-inflammatory conditions, improve hMSC properties for clinical immune 
therapy (Crop et al., 2010; Ryan et al., 2007). 
Supernatants from hMSC exert suppression of T cell activity (Najar et al., 2009; Nasef et al., 
2008a), in contrast to what has been found in hESC, where cell-cell contact is essential for 
immune tolerance (Li et al., 2004). The mechanisms by which some of these factors produced 
by hMSC act upon the immune system will be briefly explained below: 
5.2.2.1 IDO 
hMSC express the kynurenine pathway (KP) which is the central route that accounts for the 
degradation of the essential amino acid tryptophan to kynurenine and subsequently 
nicotinamide adenine dinucleotide (NAD+). KP has roles in antimicrobial activity, 
modulation of immune responses and in the creation of a tryptophan-depleted milieu that 
promotes immunosuppression (Croitoru-Lamoury et al. 2011; Munn et al. 1998). The KP 
pathway’s first and rate limiting enzyme, indoleamine 2,3-dioxygenase (IDO), has two 
isoforms IDO1 and IDO2. hMSC-secreted IDO catabolizes tryptophan necessary for rapid T 
cell proliferation. IFN-γ induces the expression of IDO in hMSC, enabling them to inhibit T 
cell proliferation and modulate the function of major cell populations involved in both the 
innate and adaptive immune systems, including APC, NK cells, T- and B-cells (Djouad et al., 
2007; Meisel et al., 2004; Uccelli et al., 2008). IDO inhibits the proliferation of activated T and 
NK cells (Krampera et al., 2006; Spaggiari et al., 2008). Also, IFN-γ-induced IDO activation in 
hMSC leads to their impaired proliferation and an alteration of their differentiation capacity 
(Croitoru-Lamoury et al., 2011). 
When IDO inhibitors were used, however, it was shown that proliferation of PBMC was not 
restored in mixed lymphocyte cultures with hMSC. Insulin-like growth factor (IGF)–binding 
proteins were shown to contribute to the inhibitory mechanism of hMSC on PBMC 
proliferation, and this effect was independent of IFNγR1 signaling and IDO expression 
(Gieseke et al., 2007). 
The mechanism of how MSC-mediated immunosuppression varies among different species 
has been investigated by Ren et al. (2009). Immunosuppression by hMSC is mediated by 
IDO whereas mouse MSC (mMSC) utilize nitric oxide under the same culture conditions. 
When the expression of IDO and inducible nitric oxide synthase (iNOS) were examined in 
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hMSC and mMSC after stimulation with the pro-inflammatory cytokine IFN-γ in 
combination with TNFα, IL-1α, or IL-1β, it was shown that hMSC expressed extremely high 
levels of IDO, and very low levels of iNOS, whereas mMSC expressed abundant iNOS and 
very little IDO. Chemokines induced by IFN-γ and TNF-α also were released by MSC of 
mouse or human origin for optimal immunosuppression to attract immune cells to the 
vicinity, including T cells, which express the chemokine receptor CXCR3 (Ren et al., 2009). 
Toll-like receptors (TLR) expressed on bone marrow-derived hMSC enhanced their 
immunosuppressive phenotype independent of IFN-γ, due to the production of 
immunosuppressive kynurenines by IDO1. Induction of IDO1 by TLR involved an autocrine 
IFN-β signaling loop, which was dependent on protein kinase R (PKR), but independent of 
IFN-γ (Opitz et al., 2009). 
5.2.2.2 PGE2 
Prostaglandin E2 (PGE2) is, like all prostaglandins, a 20-carbon oxygenated lipid-signaling 
molecule, with pro-inflammatory functions, involved in producing swelling, redness and 
pain. Prostaglandin synthesis begins with the release of arachidonic acid from 
phospholipids by phospholipase A2, and arachidonic acid is then oxygenated by 
cyclooxygenase (COX) enzymes (COX1 and COX2) expressed by hMSC to form 
prostaglandin H2 (PGH2), from which PGE2 and other prostaglandins are formed by 
specific enzymes. In the case of PGE2, they are known as PGE2 synthase enzymes: 
microsomal PGE2 synthases 1 and 2 (mPGES1 and mPGES2) and cytosolic PGES (cPGES). 
PGE2 plays a role in many immune functions, including the activation of B lymphocytes and 
the induction of Treg cells. PGE2 inhibition by indomethacin partially restored the 
proliferation of T cells in presence of MSC from human or murine origin (Aggarwal & 
Pittenger, 2005). In the clinic, the production of PGE2 has been targeted with inhibitors of 
COX-2 function to treat a range of painful and inflammatory conditions. 
PGE2 can be produced by many cells and influence the function of a wide array of immune 
cells, including T cells, B cells, NK cells, macrophages and dendritic cells. Inhibition of PGE2 
synthesis by COX inhibitors restored to a great extent in vitro T cell proliferation, while 
blocking other known hMSC-secreted inhibitors did not have the same effect. hMSC 
inhibited activated T cells proliferation and pro-inflammatory cytokines production. Thus, 
PGE2 appears to be a dominant secreted molecule involved in hMSC-induced suppression 
of an in vitro alloresponse (Yañez et al., 2010) and hMSC-mediated blocking of monocyte-
derived DC maturation (Spaggiari et al., 2009).  Also, PGE2 and IDO represent key 
mediators of the hMSC-induced inhibition of NK cells (Spaggiari et al., 2008). 
When hMSC were co-cultured with DC, high levels of PGE2 were detected. PGE2 blockade 
with indomethacin allowed maturation of plasmocytoid-DC but not myeloid-DC, and 
allowed T lymphocyte proliferation but did not restore pro-inflammatory cytokine secretion 
(Yañez et al., 2010). 
hMSC reduced the expression of MHC class II, CD40, and CD86 co-stimulatory molecules 
on mature DC, which was responsible for a decrease in T-cell proliferation. The 
differentiation of bone marrow progenitors into DC was partly inhibited when cultured 
with conditioned supernatants from hMSC, and this effect was associated, at least in part 
with the secretion of IL-6 from hMSC. Suppression of T-lymphocyte activation was partially 
counteracted by anti-IL-6 but no enhanced effects were found by IL-6 and PGE2 together 
suggesting that PGE2 may act through the induction ofg IL-6 secretion (Djouad et al., 2007). 
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When mast cells (MC) are co-cultured with mMSC to allow cell-to-cell contact, mMSC 
suppressed mast cells degranulation, pro-inflammatory cytokine production, chemokinesis 
and chemotaxis. These inhibitory effects were dependent on up-regulation of COX2 in 
mMSC and were facilitated through the activation of EP4 receptors on MC. Whether a 
similar mechanism applies to hMSC remains to be investigated (Brown et al., 2011). 
5.2.2.3 HLA-G and LIF 
HLA-G is a non-classical MHC class I molecule, which is expressed in both membrane-
bound and soluble isoforms. HLA-G expression is also claimed to be associated with 
embryo implantation, the protection of the allogeneic fetus from the maternal immune 
system, and placentation (section 3; Rebmann et al., 2010; Rizzo et al., 2011a). 
HLA-G protein expression was found to be constitutive in hMSC and the level was not 
modified upon stimulation by allogenic lymphocytes in hMSC-mixed lymphocyte reaction 
assay (Nasef et al. 2007). Furthermore, hMSC secrete the soluble isoform HLA-G5 (sHLA-
G5), which inhibits NK cell-mediated cytotoxicity and IFN-γ secretion and suppresses 
allogeneic T cell proliferation and expansion of CD4+CD25highFOXP3+ Treg cells (Morandi 
et al., 2008; Selmani et al., 2009). A summary of HLA-G functions was recently presented 
(Menier et al., 2010). The HLA-G1 isoform, not the sHLA-G5 form, has recently been found 
to be crucial for the inhibition of T-cell proliferation (Giuliani et al., 2011). 
Leukemia inhibitory factor (LIF) is a secreted glycoprotein cytokine that can inhibit the 
proliferation of myeloid leukemic cell lines and has several functions in hematopoietic 
expansion of bone marrow progenitors, pregnancy and in the humoral and cellular immune 
response. LIF and HLA-G expression in hMSC-mixed lymphocyte reactions is coordinated. 
When LIF was inhibited by a neutralizing antibody, HLA-G was not expressed (Nasef et al., 
2008b). 
5.2.2.4 Cytokines and chemokines 
An early study showed that when hMSC were prevented from cell-cell contacts in transwell 
experiments, T-lymphocyte proliferation was significantly reduced. Soluble factors such as 
TGF-β1 and hepatocyte growth factor (HGF) were proposed as mediators of T-cell 
suppression (Di Nicola et al., 2002). 
Among the secreted pro-inflammatory and anti-inflammatory cytokines, chemokines and 
prostaglandins characterized in hMSC supernatants under resting conditions is worth 
mentioning ICAM-1, IL-6, IL-8, CCL-2 and TIMP-2 (Wu et al. 2010). IFN-γ, or type II 
interferon, is a cytokine that is critical for innate and adaptive immunity against viral and 
intracellular bacterial infections and for tumor control. IFN-γ is not itself produced by 
hMSC, but originates from activated T and NK cells (Hoogduijn et al., 2010). IFN-γ is also 
known to play an important role in the induction of immune-modulatory molecules such as 
IDO (Krampera et al., 2006; see above). IFN-γ inhibited proliferation and altered human and 
mouse MSC neural, adipocytic and osteocytic differentiation via the activation of IDO 
(section 5.2.1; Croitoru-Lamoury et al., 2011). 
Upon activation, CTL produce cytokines important for their effector functions such as IFN-γ 
and TNF-α. Incubation with peptide pulsed hMSC did not lead to any detectable induction 
of IFN-γ and TNF-α secretion by specific CTLs (Rasmusson et al., 2007). 
TGF-β1 secreted by hMSC is an immunosuppressive factor capable of inhibiting NK-cell 
proliferation, cytotoxicity, and cytokine production and of downregulating the expression of 
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activating receptors 2B4 and NKG2D in NK cells. PGE2 and TGF-β1 had an additive 
inhibitory effect on NK-cell proliferation (Sotiropoulou et al., 2006). 
5.2.2.5 Galectins and Sema-3A 
Galectins are a family of β-galactoside binding proteins that bind not only to glycan 
structures expressed by host cells but can recognize β-galactoside carbohydrates on many 
pathogens. Galectins are considered as soluble pathogen recognition receptors. Within the 
immune system, galectins are expressed by virtually all immune cells, either constitutively 
or in an inducible fashion (Sioud et al., 2010; Sioud, 2011). Galectins-1 and -3 have been 
found to be main regulators of hMSC immunosuppressive function, and are constitutively 
expressed and secreted by human bone marrow MSC. Interfering RNAs abrogated their 
suppressive effect on allogeneic CD4+ and CD8+ T cells (Gieseke et al., 2010; Sioud et al., 
2010; 2011). hMSC derived galectin-1 significantly modulated the release of cytokines 
involved in GvHD and autoimmunity, such as TNF-α, IFN-γ, IL-2 and IL-10. hMSC promote 
a shift from a pro-inflammatory Th1 toward a more anti-inflammatory Th2 T-cell response 
(Gieseke et al., 2010). 
Galectin-1 is a homodimeric galactose-binding lectin with a single carbohydrate-recognition 
domain that binds to the neuropilin-1 receptor (NP-1) expressed on T cells.  The main ligand 
of NP-1 is semaphorin-3A (Sema-3A) that arrests T cells in the G0/G1 phase. Galectin-1 and 
semaphorin-3A (Sema-3A) are two soluble factors highly expressed by hMSC capable to 
inhibit T-cell proliferation through neuropilin-1 (NP-1). Blocking the interaction to NP-1 
abolished hMSC immunosuppression (Lepelletier et al., 2010). 
5.2.2.6 PD-1 ligands 
One of the well known co-stimulatory pathways is the programmed death (PD-1) pathway, 
which plays an important role in delivering inhibitory signals that regulate T cell activation, 
immune tolerance and immune-mediated tissue damage. PD-1 receptor expression is 
inducible on T cells, NK cells and activated monocytes. PD-1 interacts with the two ligands; 
PD-L1 (B7-H1; also called CD274) and PD-L2 (B7-DC also called CD273) which are 
transmembrane glycoproteins belonging to the B7 IgG superfamily (Keir et al. 2008; Petroff 
& Perchellet, 2010). The interaction leads to signalling via PD-1 receptor and deactivation of 
the immune cells such as T, B, NK, DC and macrophages, etc. While PD-L1 is widely 
expressed on low quantities in many cell types including trophoblasts, PD-L2 is more 
restricted to the myeloid cell types such as monocytes, DC and macrophages (Francisco et 
al., 2010; Petroff & Perchellet, 2010). hMSC express both PD-L1 and PD-L2 as well as several 
splice variants but their precise role in the induction of immune tolerance remains to be 
defined (Isa et al., in preparation). IFN-γ plays a critical role in triggering the 
immunosuppresion by mouse MSC through the up-regulation of PD-L1 (Sheng et al. 2008). 
Interestingly, the PD-L ligands may play a critical role in maintaining tolerance to the 
developing fetus (Petroff & Perchellet, 2010). 
5.2.2.7 CD200 
CD200 is a transmembrane glycoprotein involved in immune-modulation, such as graft 
rejection, autoimmune diseases, spontaneous fetal loss, inflammatory disorders and 
malignancy. The interaction of CD200 and CD200R on T cells results in inhibition of de-
granulation and cytokine production which mediate immune regulation through a direct 
and/or indirect action on activated T-cells via DC (Gorczynski, 2005).  CD200 is expressed in 
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hMSC suggesting that it might exert immune suppressive effects on T cells (Delorme et al., 
2008; Larsen et al., in preparation). 
5.2.2.8 Factor H 
hMSC constitutively secrete factor H, which potently inhibits complement activation, and its 
production is increased by pro-inflammatory cytokines, but suppressed by IDO and PGE2 
inhibitors. Factor H is the primary fluid phase complement regulator and it is mainly 
produced by hepatocytes in the liver. Complement is a pivotal part of the innate immunity 
whose primary roles are fighting infection and clearing out immune complexes. Excessive 
complement activation can lead to e.g. graft rejection (Tu et al. 2010). 
5.2.2.9 Serpins 
Serpins are a large family of proteins that control proteolytic cascades or have other 
cellular functions such as storage, hormone carrier proteins or tumor suppression. Serpins 
that inhibit the cytolytic enzyme granzyme B are expressed in the cytoplasm and nuclei of 
CTL and in cells of immunoprivileged sites, such as the placenta, testis, ovaries, and 
brain. In the mouse, one serpin known as serine protease inhibitor 6 (SPI6) is required to 
protect CTL from granzyme B-mediated death and facilitates the survival of virally 
infected cells and tumors. SPI6 helped mouse MSC to escape from host immune attack (El 
Haddad et al., 2011). The human orthologue of SPI6 is serpin B9 or PI-9/CAP-3, the only 
known intracellular inhibitor of granzyme B. PI-9 is expressed in many human cell types, 
but also in cancer cell lines where PI-9 is thought to protect them from granzyme B attack 
(Rousalova et al. 2010). The presence and potential role of PI-9 in hMSC remains to be 
investigated. 
5.2.2.10 Nitric oxide 
An important secreted factor that participates in suppression of T-cell proliferation is nitric 
oxide (NO) mediated by NO inhibition of transcription factor Stat5 phosphorylation.  NO is 
produced by NO synthases (NOS), of which there are 3 subtypes: inducible NOS (iNOS), 
endothelial NOS, and neuronal NO. In the presence of a direct interaction between T cells 
and mouse MSC, there was a high level of NO production accompanied by a strong 
suppression of T-cell proliferation. The presence of T cells induced the expression of iNOS in 
mouse MSC (Sato et al., 2007). hMSC also express iNOS but at lower levels than in mouse 
MSC (Ren et al., 2009). 
5.2.2.11 Heme-oxygenase 1 
Heme oxygenases (HO) are rate-limiting intracellular enzymes that degrade heme to 
biliverdin, carbon monoxide, and free divalent iron. The stress inducible form, HO-1, has 
been described as an immunosuppressive molecule and mediator of the IL-10 anti-
inflammatory cytokine. hMSC inhibited allogeneic PBMC proliferation by 60% in MLR 
experiments and HO-1 inhibition with SnPP completely abolished the immunosuppressive 
effect of hMSC (Chabannes et al., 2007). hMSC were shown to induce, in a HO-1–
dependent fashion, formation of IL-10+ Treg 1 and transforming growth factor-β+ Th3 Treg-
subsets in alloreactive and TCR-activated lymphocytes, and IL-10 production. HO-1 was 
down-regulated by soluble factors produced in the MLR and its functions were replaced 
by molecules such as COX-2. Two of HO-1 metabolic products, the heavy-chain ferritin 
and bilirubin, have been linked to Treg activation and expansion (Mougiakakos et al., 
2011). 
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6. Strategies leading to control of immunogenicity and immunotolerance of 
stem cells as means to overcome immune host responses in non-
histocompatible transplantations 
The first successful clinical organ transplantation was performed by Joseph E. Murray in 
1954 between identical monozygotic and did not require immunosuppression (Murray et al., 
2001). Successful transplantations between genetically diverse individuals require 
immunosuppression to suppress rejection by the recipient’s immune system. In spite of 
improved immunosuppressants (see below, section 7), chronic rejection is still the leading 
cause of graft failure and happens in >50% of solid organ transplants within 10 years 
(Orlando et al., 2011a).  During the first year after transplantation, the survival rates of the 
grafts are well above 90%, but the long-term survival of the graft is compromised (Li & 
Yang, 2009; Meier-Kriesche et al., 2004). Thus, immunological tolerance does not establish in 
practice. 
Acute rejection usually manifests around the time of engraftment and the incidence ranges 
between 20 and 70%, depending on the extent of histocompatibility mismatches, the age of 
the recipient and the intensity of preparative regimens, while chronic rejection resembles 
autoimmune disorders and involves B-cell dysregulation (Busca, 2011). 
Creation of custom-made bioengineered organs, where the cellular component is exquisitely 
autologous and have an internal vascular network will theoretically overcome the two major 
hurdles in transplantation, namely the shortage of organs and the toxicity deriving from 
lifelong immunosuppression. Advances in transplantation of custom-made organs have 
been described (Orlando et al., 2011b). The uses of hESC and hMSC in regenerative 
therapies will be described in section 6.1. 
6.1 Uses of human embryonic stem cells in clinical practice 
Adult stem cells have a limited lifespan and cannot be expanded endlessly to satisfy the 
numbers needed in clinical practice (Mason & Dunnill, 2009; Nehlin & Barington, 2009; 
Rayment & Williams, 2010). The earliest achievement regarding the isolation and culture of 
hESC from blastocysts (Thomson et al., 1998) suggested that their future use in regenerative 
medicine was possible.  
However, despite their low immunogenicity, hESC are still immunogenic and 
immunosuppression or tolerance induction is needed for sustained engraftment in 
allogeneic transplantation protocols. Therefore, the focus of many laboratories has been to 
try to defeat potential immunological barriers against hESC. Immunogenicity concerns 
represents a challenge of future stem cell therapy approaches (Drukker, 2004; Drukker & 
Benvenisty, 2004; Chidgey et al., 2008; Charron et al., 2009; Fairchild et al., 2004; 2007).  
Ideally, the use of self stem cells would be the most encouraging path but many technical 
issues need to be solved before it can be brought to clinical practice (Ahrlund-Richter et al., 
2009; Bongso et al., 2008; Chidgey et al., 2008; Ginty et al., 2011, Nehlin & Barington, 2009; 
Yamanaka & Blau, 2010). Several strategies involved in sustaining antigen-specific tolerance 
through interplay between Treg and DC could prolong acceptance of hESC-derived tissues 
with minimal use of immunosuppressants (Lui et al., 2009; Lui et al., 2010). However, given 
the promise of induced pluripotency (Yamanaka & Blau, 2010), stem cell transplantation 
tolerance protocols may well be displaced (Fairchild, 2009). 
Clinical immunotolerance could be achieved by a) mixed hematopoietic chimaerism or b) 
co-stimulatory blockade. Mixed chimerism involves ablation of the host immune system, 
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followed by its reconstitution with a mixture of host and donor T cell-depleted bone 
marrow. Reconstitution of the host immune system allows new emerging T cells to perceive 
the transplanted bone marrow cells as being “self”, while donor-reactive T cells are 
eliminated in the thymus or differentiate into Treg, leading to chimaeric hosts with both 
donor and self blood cells. The host needs no immunosuppression as it has become tolerant 
to the donor tissue (Ilstad & Sachs, 1984). The use of this approach has unfortunately been 
hampered by the toxic side effects inherent to conventional bone marrow transplantation 
protocols, the ablative regimen used and the use of immunosuppresants to avoid rejection 
and graft-versus-host disease (Pilat & Wekerle, 2010). 
Approaches to facilitate immune tolerance by manipulation of transplantable hESC have 
been conceived previously such as development of a universal hESC line blocking HLA 
expression, somatic cell nuclear transfer (SCNT) and creation of a HLA genotyped hESC cell 
bank. Advantages and disadvantages have been discussed in detail (Boyd & Fairchild, 2010; 
Bradley et al., 2002; Cabrera et al. 2006; Chidgey et al. 2008; Drukker, 2008; Nehlin & 
Barington, 2009; O’Rourke et al. 2008). 
A promising approach to achieve tolerance is to block co-stimulation during allogeneic 
transplantation. Co-stimulation blockade with anti-CD40L/anti-LFA-1 and CTLA4Ig 
blocking antibodies to induce tolerance to hESC transplanted into testicle, an immune-
privileged environment, and heart was examined in immunocompetent and severe 
combined immunodeficient (SCID) mice. hESC injected into the testis of SCID mice and 
costimulation blockade treated C57BL/6 mice developed into teratoma in all animals, and 
were surrounded by CD4+CD25+Foxp3+ T cells, inducing tolerance to the grafts, while in 
the control treated mice, no surviving hESC were found. Thus, co-stimulation blockade 
induced tolerance to hESC in the immune-privileged environment of the testis (Grinnemo et 
al., 2008). 
When hESC treated with co-stimulation blockade were transplanted into the hearts of SCID 
mice, hESC developed teratoma-like formations, whereas immune-competent mice 
exhibited loss of all hESC cells by 1-2 months due to lymphocytic infiltrates. However, if the 
co-stimulation blockade was repeated ~3 weeks after the initial transplantation, some 
surviving hESC-derived cells could be monitored 2 months later. Isolation of Treg from 
intramyocardial transplanted recipients treated with co-stimulation blockade demonstrated 
specificity toward undifferentiated hESC and down-regulated naive T-cell activation toward 
hESC. hESC-specific Treg developed to hESC transplanted to the heart. Thus, transplantation 
success in co-stimulation blockade treated mice was similar to that seen in SCID mice 
(Grinnemo et al. 2008b). 
Recently, a successful co-stimulatory blockade protocol was created, by simultaneous 
blocking of CTLA-4, CD40L and IRF-1 using blocking antibodies during a short period of 6 
days. Experimental mice were transplanted with e.g. transgenic human iPS or hESC, and 
their fate was examined using bio-imaging. The donor cells were able to survive and grow, 
and after 54 days, there was no evidence of rejection (Pearl et al., 2011). This finding 
suggested that allogeneic hESC transplantation with a brief co-stimulation blockade of 
leukocyte co-stimulatory pathways could be feasible. Unfortunately, the long-term effects of 
such procedures with respect to the risk of infections are not yet known. 
The idea of creating a cell bank composed of donor HLA-typed hESC lines representing 
different haplotypes matching those of a large population that would help to reduce the risk 
of graft rejection and satisfy unmet clinical needs was envisioned (Taylor et al. 2005). 
However, a perfect 6/6 match between donor and recipient in terms of classical MHC class I 
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HLA-A,-B and –C alleles would not be enough to prevent rejection. Allograft survival is 
inversely correlated with the degree of mismatch between the donor’s and the recipient’s 
MHC antigens. The ideal transplant that carries lessened risk of rejection is the one where a 
perfect 12/12 match is ensured, whereby in addition to identical HLA-A,-B,-C between 
donor and recipient, also identical MHC class II proteins HLA-DR, -DP, and –DQ are sought 
(Loiseau et al. 2007). It appears unrealistic to build a stem cell bank of the required 
magnitude in order to match all HLA genotypes world wide. Also, even minor 
histocompatibility antigens may pose a risk (Bradley et al., 2002; Charron et al. 2009; Feng et 
al., 2008; Shlomchik, 2007; Spencer et al., 2010). 
To assess if hMSC could be used to induce tolerance to co-transplanted hESC, ligation-
induced myocardial infarction was performed in immunocompetent rats and 3 weeks later 
the hearts were injected with either hMSC, hESC or both. Co-transplantation of hESCs and 
hMSC provided better preservation of left ventricle function compared with single-cell 
treatment alone. The lack of clear evidence for an immunosuppressive or tolerogenic action 
of hMSC suggested that the benefits observed were mediated by synergistic trophic effects 
that enhanced repair of injured host tissue (Puymirat et al. 2009). 
hESC could also be used in therapies to inhibit tumor progression. Supernatants from hESC 
have been shown to reduce the clonogenicity and tumorigenesis, as well as to increase 
apoptosis in aggressive cancer lines (Postovit et al., 2008). 
The  world’s first clinical trial involving the use of hESC-derived cells is ongoing. A cell line 
known as GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have 
demonstrated remyelinating and nerve growth stimulating properties leading to restoration 
of function in animal models of acute spinal cord injury. A phase I study has been initiated 
to assess safety and tolerability in a paralyzed patient with spinal cord injury. Each 
transplant recipient will be immune-suppressed from the time of injection with low-dose 
tacrolimus for 46 days, at which time the immune suppression will be tapered and 
withdrawn at 60 days (www.geron.com/GRNOPC1Trial/). 
6.2 Uses of human mesenchymal stem cells in clinical practice 
The first published human clinical study reporting positive results with hMSC was in a 
young boy with acute lymphoblastic leukemia in third remission that had received a 
transplant of blood stem cells from an HLA-A, HLA-B, HLA-DR1 identical, unrelated, 
female donor, but after 70 days, developed grade IV GvHD unresponsive to conventional 
therapy. Transplantation of his mother’s hMSC exerted such a strong immunosuppressive 
effect in vivo that the patient made a remarkable recovery (Le Blanc et al., 2004). 
After this successful case, the profound inmuno-modulatory and anti-inflammatory effects 
of hMSC have been exploited for clinical applications in a number of clinical trials to treat 
diseases such as hematological malignancies, autoimmune diseases such as Crohn’s, type 1 
diabetes, rheumatoid arthritis, systemic lupus erythematosus, neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and  multiple 
sclerosis, In addition, hMSC are included in prospective studies to prevent GvHD, treat 
refractory GvHD, cancer, stroke, acute myocardial infarction, critical limb ischemia, acute 
tubular necrosis, and use in plastic surgery, bone and cartilage tissue engineering, wound 
healing, dental pulp regeneration, heart transplantation, insulin-dependent diabetes 
mellitus, etc. (Abdi et al., 2008; Aggarwal & Pittenger, 2005; Dazzi et al., 2007; Doeppner & 
Hermann, 2010; Kan et al., 2007; Le Blanc & Ringden, 2007; Niemeyer et al., 2006; Sasportas 
et al., 2009; Sato et al., 2010; Singer & Caplan, 2011; Trento & Dazzi, 2010; Tögel & 
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Westenfelder, 2007; Vanikar et al., 2010; Wu et al., 2010). Several clinical trials where bone 
marrow hMSC have been used in the treatment of ischemic heart disease such as in clinical 
refractory angina, ischemic cardiomyopathy with left ventricular dysfunction, and end-stage 
heart failure have yielded promising results (Fuh & Brinton, 2009). Prochymal, a commercial 
hMSC line, underwent a successful clinical trial to treat myocardial infarction, giving 
insights into the preparation of hMSC (Hare et al., 2009). More recently, another study 
demonstrated that it was safe to treat patients with stable coronary artery disease, with 
autologous hMSC, showing significant improvement in left ventricular function, exercise 
capacity and clinical symptoms (Friis et al., 2011). 
A summary of pre-clinical models and clinical trials where in vitro expanded hMSC were 
used and where the biological properties of hMSC were explained in detail have recently 
been reported (English et al., 2010; Garcia-Gomez et al., 2010; Parekkadan & Milwid, 2010; 
Salem & Thiemermann, 2010; Shi et al., 2011; Singer & Caplan, 2011). hMSC supported 
engraftment and survival of unrelated human donor hematopoietic stem cells infused into 
sublethally irradiated NOD-SCID mice (Maitra et al. 2004). The biological effects of MSC in 
mouse and rat pre-clinical models of disease have also been reported (Uccelli et al., 2008). 
hMSC have the capacity to migrate (homing) and integrate into damaged tissues and 
provide immunomodulatory effects by paracrine (soluble factors) and/or cell-cell contact 
that is regulated by the inflammatory microenvironment. Local or systemic infusions are 
now being successfully used to co-transplant hMSC with other parenchymal cells, such as 
hepatocytes or islet cells, to enhance the engraftment and function of such cells in an 
immunoprotected fashion. These findings may extend future prospects of the clinical 
application of MSC into broader applications (Uccelli et al., 2008; Yagi et al. 2010). After in 
vivo administration, MSC induce peripheral tolerance and migrate to injured tissues, where 
they can inhibit the release of pro-inflammatory cytokines and promote the survival of 
damaged cells (Uccelli et al. 2008). 
hMSC are easily isolated from bone marrow, fat and other tissues, and are readily 
propagated in vitro. Transplanted/injected MSC have been shown to migrate to a variety of 
organs and tissues, but they preferentially undergo homing to sites of inflammation and 
pathology for tissue remodeling and repair. Transplanted allogeneic MSC can be detected in 
recipients at extended time points, indicating a lack of immune recognition and clearance 
(Singer & Caplan, 2011). Because tumor microenvironments also appear to be a target of 
hMSC homing, there are various controversies surrounding these interactions regarding 
clinical outcomes (Kidd et al., 2008). hMSC have been used to secrete recombinant cytokine 
tumor necrosis factor apoptosis ligand (TRAIL) to induce apoptosis of glioma cells in vivo 
(Sasportas et al., 2009). Another study has shown that hMSC exhibit innate anti-tumor 
effects against human pancreatic carcinoma cells implantated in SCID mice and can serve as 
delivery vehicles for IFN-β for the treatment of pancreatic cancer (Kidd et al., 2010). Also of 
great concern is the potential tumorigenicity of hMSC. Although malignant transformation 
of primary hMSC has not been noted to date in clinical trials using hMSC, expansion in vitro 
for extended periods of time could confer the risk of chromosomal instability and malignant 
transformation as was reported for mMSC (Tolar et al., 2007). 
The strong immunosuppressive activity of MSC has been exploited to attempt treating 
GvHD (Dazzi & Marelli-Berg, 2008). The clinical experience with hMSC for the treatment of 
GvHD is encouraging but incomplete. Results of clinical trials utilizing hMSC for the 
treatment of acute and chronic GvHD have been summarized (Kebriaei & Robinson, 2011). 
Longer follow-ups of current clinical trials are necessary to determine whether any long-
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term unwanted effects are associated with the use of hMSC to treat GvHD (Kebriaei & 
Robinson, 2011). 
Clinical trials involving hMSC for the treatment of GvHD have been recently described 
(Sato et al. 2010). Infusion of hMSC expanded in vitro, irrespective of the donor, might be 
effective therapy for patients with steroid-resistant, acute GvHD (Le Blanc et al., 2008).  
hMSC appear capable of suppressing acute GvHD without increasing systemic infections 
(Sato et al., 2010). Donor hMSC significantly inhibited the proliferation of alloactivated 
recipient T cells before and after kidney transplantation suggesting that the application of 
hMSC in solid organ transplantation may facilitate graft acceptance and function (Crop et 
al., 2009). 
Steroid-refractory GvHD may also be treated with hMSC infusions but hMSC have been 
almost impossible to detect after infusion when administered in vivo, and thus little is 
known regarding their migration, their mechanism of action, or their persistence (Paczesny 
et al., 2009). Advances in the immune reconstitution after hematopoietic stem cell 
transplantation (HSCT), a widely used method in cancer treatment have been reviewed 
elsewhere (Cavazzana-Calvo et al., 2009). One trial example involved co-transplantation of 
ex vivo-expanded donor hMSC with CD34+ cells from a relative in children with a 
hematological malignancy, leading to a reduced risk of graft failure in haploidentical 
hematopietic stem cell- transplant recipients (Ball et al., 2007). However, relapse of the 
underlying disease, GvHD, or severe opportunistic infections, account for the majority of 
deaths following HSCT. Approaches such as immune reconstitution,  withdrawal of the 
immunosuppression, chemotherapy or novel drugs with or without donor lymphocyte 
infusions, and even second allogeneic stem cell transplantation are considered (Kröger, 
2011; Seggewiss & Einsele, 2010). Cellular therapy including adoptive transfer of ex vivo–
expanded immunomodulatory cells such as Treg cells, NK/Treg cells, donor-derived NK cells, 
and hMSC and adoptive transfer of allogeneic T cells specific for viral or tumor antigens 
appears promising to improve immune reconstitution after transplantation (Peters et al., 
2009; Seggewiss & Einsele, 2010). 
Immune responses against hMSC has also been studied in a kidney transplant setting. 
Donor hMSC and kidney recipient immune cells (PBMC) isolated at various time points 
after kidney transplantation were used in MLR assays. Donor hMSC significantly inhibited 
cytotoxic effector cells of the recipients isolated before transplantation. Allogeneic hMSC 
were susceptible to lysis by cytotoxic CD8+ T-cells and NK cells, while autologous hMSC 
were lysed by NK cells only. NK cell-mediated lysis was inversely correlated with the 
expression of HLA class I on MSC. PBMC isolated 3, 6 and 12 months after donor kidney 
transplantation showed increasing lysing ability against donor hMSC. Even 12 months after 
kidney transplantation, CD8+ T cell-mediated lysis of donor hMSC persisted, indicating that 
there was no evidence for desensitization against donor hMSC. Therefore, controlling the 
immunogenicity conferred by the HLA expression status, the survival over time of hMSC 
and avoidance of lysis by cytotoxic immune cells are important for the efficacy of MSC 
therapy in organ transplantation (Crop et al., 2009; Crop et al., 2011). 
Treatment with allogeneic hMSC or the conditioned medium restored alveolar epithelial 
fluid transport and lung fluid balance in an ex-vivo perfused human lung preparation 
injured by E. coli endotoxin, and keratinocyte growth factor played a crucial role in this 
effect (Lee et al., 2009). 
Also, the use of inducible Treg or T regulatory type 1 cells are promising  candidates for stem 
cell therapy because of their immunomodulatory activities such as ability to secrete 
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suppressive cytokines and cell-to-cell contact-dependent killing of target myeloid cells 
mediated by granzyme B and perforin. Such properties are helpful not only to inhibit GvHD 
after allogeneic hematopoietic stem cell transplantation, but also in other transplantation 
settings, or to re-establish tolerance in autoimmune or allergic diseases (Peters et al., 2009; 
Roncarolo et al., 2011). 
Although shown in a mouse sepsis model, it was found that injections of bone marrow 
mMSC protected cells from damage in affected vital organs and had reduced vascular 
permeability, one of the deadliest consequences of sepsis. The therapeutic effect was 
mediated by reprogramming of the macrophage after direct contact with MSC, resulting in 
macrophage-dependent production of IL-10 and lower expression of TNFα and IL-6. PGE2 
from MSC after activation of Toll-like receptor 4 by bacterial lipopolysaccharide (LPS) was 
responsible for the reprogramming (Nemeth et al., 2009). Also shown in a mouse model 
very recently, it was found that intramyocardial delivery of c-kit+ bone marrow cells after 
myocardial infarction induces endogenous progenitor-derived cardiomyocyte renewal and 
improves ventricular function, an effect not observed with MSC (Loffredo et al., 2011). 
Recently, methods have been developed to identify hMSC with the highest 
immunosuppressive capacity based on soluble HLA-G production (HLA-G5) in IL-10-
treated bone marrow hMSC. A decreased positivity for CD90 is associated with loss of 
immunosuppressive capacity (Rizzo et al., 2011b). 
Pre-clinical screening before allogeneic stem cell therapy is possible if isolated hMSC can 
undergo a cytotoxicity assay by means of mixed lymphocyte cultures and the subsequent 
measurement of their proliferation potential (Koppula et al., 2009). 
hESC-derived hMSC demonstrated having immunosuppressive effects towards T and NK 
cells, similar to natural hMSC suggesting another origin from which hMSC can be obtained 
for therapy (Yen et al., 2009). As mentioned previously, the possibility of reprogramming 
self-cells into hESC from which one could develop the cell type and numbers needed for a 
given therapy, would be an ideal situation.  
Many challenges need to be assessed in the future as regards the characterization and 
quantities of stem cells necessary for regenerative medicine which may vary by several orders 
of magnitude depending on the conditions to treat and their needs among the millions of 
people afflicted worldwide by a number of degenerative illnesses. Follow-up studies to 
understand the long-term in vivo effects of allogeneic transplantations are needed (Mason & 
Dunnill, 2009; Rayment & Williams, 2010). Also, optimization of the growth conditions to 
preserve hMSC immunomodulatory properties are merited (Samuelsson et al., 2009). 
Although hMSC exhibit immune privileges as explained above, allogeneic hMSC infused 
intravenously into the host without immunosuppression or chemotherapeutic conditioning 
may still lead to adverse effects that require treatment. The purpose of deliberately induced 
immunosuppression in a host recipient is to prevent rejection during transplantation of non-
histocompatible (allogeneic) cells, tissues or organs, and to treat GvHD. However, the use of 
immunosuppresants increases the vulnerability of the individual to opportunistic infections, 
nephrotoxicity, cancer and even accelerated aging (Li & Yang, 2009; Nehlin and Barington, 
2009). Several families of immunosuppressants have been developed such as 
glucocorticoids, cytostatics, therapeutic monoclonal antibodies, and many others (Duncan & 
Wilkes, 2005). In the case of allogeneic hematopoietic stem cell transplants, even though 
response rates were reported to be more than 60%, long-term survival still remains sub-
optimal, mainly due to the detrimental side effects of infectious complications, progressive 
GvHD and relapse due to the underlying malignancy (Busca, 2011). 
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7. Conclusion 
hESC are pluripotent stem cells with low immunogenicity and  immune-modulating 
properties conferred by molecules intrinsic to the cells themselves, but also found secreted 
in the microenvironment. Many studies remain to ascertain the role of the various 
components acting upon immune system cells in allogeneic settings. This is especially 
merited if off-shelf cell lines from hESC banks will be used in the future.  
In-depth immunological characterization of iPS cells is required to envision their use in 
auto-transplantation protocols and clinical trials to reveal if any potential incompatibility 
might arise as a result of the reprogramming process.  Reprogrammed cells (iPS) will offer 
great clinical advantages once potential hurdles are fully sorted out. 
Multipotent stem cells such as hMSC are endowed with multiple immune-regulatory 
properties acting on different cells of the immune system that protect them from cytotoxic 
effects. The regulation and quantification of the hMSC-dependent immune-suppression 
properties both in vitro and in vivo in long-term transplantation studies await further 
analyses. The therapeutic uses of hMSC are becoming widespread in a number of clinical 
conditions, but its place in future medicine still needs to be clarified. 
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